1. Home
  2. XCBE vs VCRE Comparison

XCBE vs VCRE Comparison

Compare XCBE & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XCBE

X3 Acquisition Corp. Ltd. Class A Ordinary Shares

SELL

Current Price

$10.06

Market Cap

282.1M

Sector

N/A

ML Signal

SELL

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

N/A

Current Price

$9.41

Market Cap

271.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
XCBE
VCRE
Founded
2025
2000
Country
United States
Sweden
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
282.1M
271.7M
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
XCBE
VCRE
Price
$10.06
$9.41
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $24.45
AVG Volume (30 Days)
★ 37.5K
16.7K
Earning Date
N/A
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$38.94
Revenue Next Year
N/A
$694.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.75
$7.88
52 Week High
$10.09
$14.01

Technical Indicators

Market Signals
Indicator
XCBE
VCRE
Relative Strength Index (RSI) 74.85 42.49
Support Level $9.88 $8.83
Resistance Level N/A $9.64
Average True Range (ATR) 0.01 0.44
MACD 0.00 -0.10
Stochastic Oscillator 62.50 12.45

Price Performance

Historical Comparison
XCBE
VCRE

About XCBE X3 Acquisition Corp. Ltd. Class A Ordinary Shares

X3 Acquisition Corp Ltd is a blank check company.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: